

Indian patent opposition proceedings in recent years

Karra Santhosh Reddy
Nalsar University of Law, India

The objective of this paper is to provide the information regarding pre grant, post grant oppositions filed on the basis of different grounds and the petitions for revoking the earlier granted patent. Any person if interested shall be filed pre grant opposition after publication by way of representation but before the date of grant, based on section 25(1) and rules 55 (1 to 6). Post grant opposition can be filed at any time after the grant of patent, before the expiry of a period of 1 year from the date of publication of grant of patent based on section 25(2) and rules 55A to 63. Revocation of patent on request by opponent in the case of obtaining stand on section 26(1), section 26(2) and the rule 63A. Revoking the granted patent on the petition of central government depend on section 64, section 65 and section 66. Revocation by any person interested under compulsory licence connected with section 85. This presentation gives information that, what are the companies filing oppositions, what are the companies losing their patents, on the basis of which grounds number of oppositions are succeeding in recent years and the revocations happened in recent years and the companies got compulsory licences in recent years.

Biography

Karra Santhosh reddy has completed his PG Diploma course in patent law from NALSAR University (Hyderabad), bachelor and masters in pharmacy from Kakatiya University (Warangal).

santhoshcare2006@gmail.com

Biogenerics: Present status in India

Karthik Chandra B. S, Tanmoy Das and N. Vishal Gupta
JSS University, India

Biologic drugs (or follow-on biologics/Biosimilars) refer broadly to substances produced by living cells which are used in the treatment, diagnosis or prevention of diseases. India has witnessed a significant growth in biogeneric industry and it is expected to grow exponentially in the years to come. According to a leading industry report by BioPlan Associates, India currently holds 8% of the world's biomanufacturing potential and has forecasted it to grow further in size. India offers several advantages that make it a force to reckon with in Biogenerics, having said that, there are also some challenging issues that need to be addressed for India to become an acknowledged leader in biogenerics. Some prominent companies engaging in biogeneric industry are Biocon, Dr. Reddy's, Shantha Biotech, Ranbaxy and Wockhardt. This study aims to give an overview of the current market scenario of biogeneric products in India.

Biography

Karthik Chandra B S is a student of JSS College of Pharmacy, JSS University, Mysore, Karnataka, India. He has completed his B.Pharm from H.K.E's college of pharmacy under Rajiv Gandhi University of Health Sciences, Bengaluru. He is currently pursuing M.Pharm in Pharmaceutics at JSS College of Pharmacy, Mysore.

shanmukhakarthik@hotmail.com